zilovertamab vedotin
1 abstract
Abstract
Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.Org: University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Indiana Blood and & Marrow Transplantation, Franciscan Health, Karmanos Cancer Institute, Oslo University Hospital, Division of Cancer Medicine, Oslo, Norway, Sungkyunkwan University School of Medicine, Samsung Medical Center,